OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

An investors take on yesterdays the AGM :-






In order:-

"The AGM
Was run through quickly. The only issue being that whilst approval was given (on proxies) for the company to increase the share capital by up to 2/3rds WITH pre-emption rights, but the resolution 12 was withdrawn after pressure from big investors. It would have given them the right to allot 10% of share capital on a sale WITHOUT pre-emption rights.
Instead they will have to call a shareholder meeting if they need to do this.

PRESENTATIONS
1. John Dawson - "Headlines"
A run through of Ocular, Trovax, and Prosavin... highlight comment "We HAVE Trovax proof of efficacy...."

2. Stuart Naylor - detail progress
Slide by slide review of the whole product set.

Lentivector.... regulators now have 2 complete years of safe, well tolerated, no side effects
experience in man. Every subsequent application to the regulators for a gene delivery comes with this increasing body of evidence. The Prosavin programme has been slower than they would have liked but "at French regulator pace". They are adding a British centre (in Cambridge)to the French one, which will help broaden the capacity. However, he says, we need to realise just how conservative the regulators are regarding the risk of introducing a gene
into a human brain.
Very confident, lots of added "anecdotal" information which he believes cannot be released to the market, but helps to explain why their confidence is SO high. e.g. ALL Prosavin patients were at the end of their L-dopa and suffering swings between dyskinesia and off states. There are golfers now doing a full round, patients living normal lives and even one who has "taken up DIY"! "UDPRS scores tell something but not the quality of life story."
The animal model has shown that the new infusion method has a much more significant improvement at lower dose levels. If repeated in human trial they may not need to escalate further two levels (which they have permission to do).
Prosavin P3 expected to commence in 2011.

Ocular progress as planned, two of these into clinical trial in man in Q4 2010.

"We have clarity on Trovax and the evidence to support efficacy."
Trovax would/will pass a restructured phase 3 now, with what has been learned about blood state.
Their view is that a partner is required to fund a large trial and they don't plan to fund one themselves. Instead they are funding at low levels a series of P2 trial with randomisation and placebo arms.

3. John Dawson - Strategy

He is keen on Mergers and acquisitions and has restructured the company so as to be capable of delivering deals and handling M & A. Gave a "personal success CV" to support these assertions.

Prosavin deal is potentially near. He HAS a term sheet but is still not happy about "one or two of the terms offered". "Will not accept any deal, only the right deal".

Trovax. A number of "suitors" at "early discussions".

M & A - "ongoing evaluation of opportunities."

Sees the financial potential for lead products as follows (in ANNUAL revenues):-
Prosavin $850m peak sales in EU and US
Retinostat $850m
Trovax >$1Bn ("many indications")

4. Q & A

Agreed Prosavin not as well known as they would like. Now have a couple of USA luminaries on the DSMB which should help. But problem IS understood.

What happened to QASAR? - "We missed the boat. At the time that the funding became actually available the TRIST issues were not at all clear."

How long would a Prosavin P3 trial be, given they (the authorities) would have 3 years safe dosage and efficacy knowledge by the time it starts? Probably only one confirmatory trial, 1 year.
So would that mean 2012 approval? "Probably too optimistic".

"However, if the infusion method should deliver results like the pre-clinical, there is the potential for significant acceleration."


5. "INFORMAL" Discussion

I asked Dawson if he speaks to the corporate investors, or are OXB too small an investment?
"I speak to all of them. Especially M & G, who I speak to very often".

Asked Prof Kingsman "you once famously said you wouldn't accept less than 1 per share? Big grin... "Things have changed I guess but I am guessing that your corporate investors are on averages around 25p to 30p, wouldn't you think?" AK: "Probably slightly less, but around that, yes."

AK still considers Prosavin "as good as a cure" and is confident in Trovax efficacy."

More good newsbut I doubt it will affect the SP

RNS Number : 9874N
Oxford Biomedica PLC
24 June 2010








OXFORD BIOMEDICA ANNOUNCES COLLABORATIVE PHASE I/II STUDY TO EVALUATE TROVAX IN MESOTHELIOMA



Oxford, UK - 24 June 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, is pleased to announce that it has entered a collaboration with a team of cancer immunologists led by Dr Zsuzsanna Tabi at Cardiff University and in partnership with Dr Jason Lester, an oncologist at Velindre Cancer Centre in Cardiff, to evaluate TroVaxin a Phase I/II study in mesothelioma. The study will be funded by the June Hancock Mesothelioma Research Fund (JHMRF) and Oxford BioMedica will provide TroVax its therapeutic cancer vaccine. The study aims to examine the effect of TroVaxin combination with first-line chemotherapy agents Alimta and cisplatin as a treatment against mesothelioma. This study follows a feasibility project undertaken by Dr. Tabi and her team which was also funded by the June Hancock Mesothelioma Research Fund.

Commenting on today's announcement, Dr Tabi said: "We are very excited aboutconducting this cancer vaccine trial in mesothelioma patients. The continuing support of our work by the June Hancock Fund and collaboration with Oxford BioMedica made this trial possible for which we are very grateful. We hope that patient recruitment can start later in the year."

Therapeutic cancer vaccines can be used in a number of ways. They can be injected into patients to stimulate the body's own defence system to produce immune cells and antibodies which attack the cancer cells by targeting specific markers (antigens) on them. Alternatively, cell-based immunotherapies use the patients' own immune cells, treated in the laboratory to fight cancer cells more effectively, before injecting them back into the patient. TroVaxis a cancer vaccine which targets 5T4, a protein expressed on most common tumour types and which has recently been shown to be present on mesothelioma cells by Dr Tabi and her colleagues. TroVaxhas been shown to be safe and effective at inducing immune responses in other types of cancer but this study will be the first time that it will be used as a treatment for mesothelioma in the UK.

Stuart Naylor, Chief Scientific Officer of Oxford BioMedica, commented: "We are very pleased to have the opportunity to continue to work with the JHMRF and our colleagues at Velindre Hospital. The pioneering work undertaken by Dr. Tabi and her colleagues has identified 5T4 as an exciting new therapeutic target in mesothelioma, a disease which has few treatment options available to patients."

JHMRF is constantly seeking to advance the range and type of treatments on offer to patients by supporting high quality research and exploring novel approaches. JHMRF trustee Dr Kate Hill commented: "The JHMRF is delighted to continue its association with Dr Tabi. The Cardiff immunology team is well established in its field and has shown a tremendous commitment to working with the JHMRF to pursue research in mesothelioma. There are never guarantees in any type of experimental research but we believe that immunotherapy has great potential in the treatment of mesothelioma."

Immunotherapy may offer new ways of attacking tumours by targeting the unique markers on cancer cells. Dendreon, a US biotech company, recently became the first to have a cancer vaccine approved by the US drug licensing agency. It is hoped that this breakthrough demonstrates the potential of immunotherapy products and will stimulate further investment which will ultimately lead to cancer vaccines becoming a standard tool in the oncologist's armoury.

If a Medical Team of Cancer Immunologists are prepared to collaborate with OXB it rather tells the story that Trovax has real potentialcharitably funded to boot!

It seems that there are many that have the confidence and knowledge happy to invest in OXB researchthe publicity dont go a miss either

Business Financial Newswire - Gene therapy company Oxford BioMedica has announced a 255,000 grant by the Motor Neurone Disease Association to fund a collaborative project with Belgium's VIB research institute.

The grant will support further preclinical evaluation of MoNuDin, which is based on Oxford's advanced LentiVector gene-delivery technology, for the treatment of ALS or Lou Gehrig's disease.

Off pisteAlan Greenspan live on CNBC right now

Oxford Biomedica PLC
26 July 2010




OXFORD BIOMEDICA ANNOUNCES FDA APPROVAL FOR TROVAX PHASE II STUDY IN PROSTATE
CANCER

Oxford, UK - 26 July 2010: Oxford BioMedica plc ("Oxford BioMedica" or "the
Company") (LSE: OXB), a leading gene therapy company,announces that it has
received approval from the US Food and Drug Administration (FDA) and Recombinant
DNA Advisory Committee (RAC) to initiate a clinical Phase II study in the United
States to assess the activity of TroVax(MVA-5T4) in patients with progressive
hormone refractory prostate cancer (HRPC).
The randomised, open-label Phase II study will enroll 80 patients with
metastatic HRPC in five centres across the US and will assess the activity of
TroVaxplus chemotherapy drug Docetaxel (Taxotere ), versus Docetaxel alone.
The study will be led by Professor Anna Ferrari, NYU Clinical Cancer Center, and
is anticipated to be initiated by the end of Q3 2010.
Prostate cancer is the second most common cancer in men worldwide. Prostate
cancer hormone therapy involves the removal of the body's testosterone supply
which, for a period of time, will slow or stop the growth and spread of prostate
cancer. Hormone refractory prostate cancer occurs when hormone therapy fails to
stop the growth of prostate cancer.
John Dawson, Chief Executive Officer at Oxford BioMedica, said: "Receiving FDA
and RAC approval is a significant final step in the planning of this study
of TroVaxin patients with HRPC and follows positive analysis of the TRIST
clinical study. We intend this study to be followed by a series of
investigator-led clinical studies and we are pleased to continue the clinical
development of TroVax With the study design now in place, we look forward to
recruiting our first patient and advancing the development of TroVaxin an
important disease area."
-Ends-

Yes, yes, the RNS is easier to read itself - what are your thoughts on the news?

Personally, I'm surprised this trial (ann 26July10) will be over so quickly, but then it's PhII with few patients. What is more important IMHO is the Co. is now addressing male-health issues......far too often "cancer" means (female) breast cancer.
OXB is rather slow in commercialising I fear. I've waited rather too long and may go elsewhere . . . this was my No1 holding, but devasating News has removed that status.

HangonI am invested here for a number of reasons.first of all John Dawson is on record as saying on more than one occasion Prosavin deal is potentially near. . "Will not accept any deal, only the right deal".many investors have been disappointed in Prosavin as results in humans have been short compared to results in the monkeysbut dosage is also lessa 5x could see a difference also Sanofi had a lot of say in the direction oxb went with Trovaxthey paid the bills the company have never said that it was a cure for cancerIt's a vaccine that helps your body fight the diseaseand that is the direction it is now goingno SP value of Trovax is currently priced inwith the latest couple of rns this cannot be right?oxb have plenty of cashbut also could get payments should Retinostat start trialsand lastly it is not beyond the possibility that Sanofi-Aventis come in for oxbthe 10p SP imo has no danger downside the up-side could be interesting?

Pharma Times

BioMedica gets US green light for Trovax trial
26 July 2010
Shares in UK group Oxford BioMedica were on the rise yesterday after it emerged that the company has received clearance from regulators across the pond for a mid-stage trial of its cancer vaccine Trovax.

Both the Food and Drug Administration and Recombinant DNA Advisory Committee have now given a seal of approval for a Phase II study in the US to assess the activity of Trovax in patients with progressive hormone refractory prostate cancer, the second most common cancer in men worldwide.

The decision means that the planned trial - which will be randomised and open label in nature, and should enrol around 80 patients with the disease - can kick off by the end of the third quarter, assessing a regimen of Trovax and the chemotherapy Docetaxel compared to the latter alone in five centres across the country.

The news should be particularly welcomed by the firm as Trovax, targets the tumour antigen 5T4, suffered a significant setback in 2008 after missing a primary endpoint in renal cancer trial. However, following a review of data from the Phase III TRIST study, US regulators approved the companys plans for further development of the cancer vaccine last year.

Clearance of this Phase II trial in prostate cancer follows positive analysis of the TRIST data, and the firm intends this trial to be followed by a series of investigator-led clinical studies, noted John Dawson, Oxford BioMedicas chief executive.

The groups shares closed up 3.74% on the London Stock Exchange following the news.

By Selina McKee

Emergent Licensing Agreement



TIDMOXB

RNS Number : 2314R
Oxford Biomedica PLC
18 August 2010



OXFORD BIOMEDICA ANNOUNCES LICENSING AGREEMENT WITH EMERGENT BIOSOLUTIONS INC.

Oxford, UK - 18 August 2010: Oxford BioMedica ("the Company") (LSE: OXB), a
leading gene therapy company, today announces that it has signed a licensing
agreement with Emergent Product Development Germany GmbH ("Emergent"), a
wholly-owned subsidiary of Emergent BioSolutions Inc. The agreement grants
Emergent non-exclusive rights to Oxford BioMedica's Hi-8 PrimeBoost technology
patents and a sub-licence under poxvirus patents licensed to the Company for the
development and commercialisation of vaccines and therapeutics targeting eight
infectious diseases, including Tuberculosis.

Under the terms of the agreement Emergent will pay an upfront licensing fee of
$1 million, potential milestone payments of up to $20.4 million, and undisclosed
royalties on sales. The milestone payments are based on specified development
successes, including the initiation of future clinical trials, and will be paid
out over several years. One such milestone includes the initiation of a Phase
III trial for the Tuberculosis vaccine candidate being jointly developed by the
Oxford-Emergent Tuberculosis Consortium (OETC) Ltd., a collaboration between
Emergent Product Development UK Ltd. and the University of Oxford.

An effective vaccine usually requires more than one immunisation.
Traditionally, vaccines are given multiple times as "homologous" prime-boosts
using the same delivery system or "vector". Heterologous prime-boost
immunotherapy involves priming the immune system to target an antigen using one
vector and then boosting the response by administration of the same antigen
using a different vector. In many cases this can elicit immune responses of
greater magnitude and breadth than can be achieved by priming and boosting with
the same vector. Oxford BioMedica's Hi-8 PrimeBoost technology is based on the
use of DNA vaccines and recombinant viral vectors.
John Dawson, Chief Executive Officer at Oxford BioMedica, said: "Emergent has a
diverse pipeline of vaccine products and is therefore another strong licensee of
our heterologous prime-boost technology patents."
-Ends

So this licensing agreement could be worth $20-30 mil. over the coming yearsall for non-exclusive rightsand the upfront $1mil. is nicea little vague with the wording potential and undisclosed anyway it is a no lose dealbut i cant see the sp going ballistic25mins to find out?

Panmure:
Oxford BioMedica:-
Oxford BioMedica will report interim results in Tuesday, 24 August 2010. We forecast that the company will report revenues of 3m, with R&D investment of 6m and admin costs of some 1.4m, resulting in EPS of -0.56p. We reiterate our Buy recommendation and 17p price target.
-o-

Half Yearly Report



TIDMOXB

RNS Number : 5080R
Oxford Biomedica PLC
24 August 2010

?

OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2010

Oxford, UK - 24 August 2010: Oxford BioMedica plc ("Oxford BioMedica" or "the
Company") (LSE: OXB), a leading gene therapy company, today announces its
unaudited interim results for the six months ended 30 June 2010. Year to date
highlights include:

Operational highlights:
ProSavin : Parkinson's disease
� Two-year Phase I/II data show long-term benefit of treatment
� Enhanced administration technique approved and used to treat seventh and
eighth patient in the study
� Treatment of final dose cohort expected to start in Q1 2011

Ocular programmes
� Regulatory applications to support clinical development of RetinoStat
and StarGenTM to be submitted by year-end
� Phase I/II trial initiation: RetinoStat expectedin Q4 2010, StarGenTM
expected in Q1 2011
� All four products expected to be in clinical development in 2011
� First RetinoStat and StarGenTMresults expected in 2012

TroVax : cancer vaccine
� FDA and RAC approval received to initiate a Phase II study in hormone
refractory prostate cancer; trial expected to start in Q3 2010
� Phase I/II sponsored study in mesothelioma expected to start in Q1 2011
� Discussions on-going for sponsored trials in other cancer indications
including ovarian cancer

Financial highlights1:
� Revenue of GBP5.3 million (H1 2009 GBP13.9 million, H1 2009
pre-exceptional GBP4.0 million)
� Research & Development costs of GBP8.0 million (H1 2009 GBP11.6 million,
2009 pre-exceptional GBP7.8 million)
� Net loss of GBP2.9 million (H1 2009 GBP0.5 million, H1 2009
pre-exceptional GBP5.7 million)
� Net cash burn2 of GBP9.2 million (H1 2009: net cash generated2 of GBP12.7
million)
� Net cash3 of GBP16.3 million (H1 2009: GBP34.8 million)
� Financial resources sufficient to fund operations into Q1 2012

1. Unaudited results
2. Net cash generated by/used in operating activities plus sales and
purchases of non-current assets
3. Cash, cash equivalents and available for sale investments

Post period end highlights:
� GBP1.7 million cash receipt from sanofi-aventis in July 2010
� Licensing agreement with Emergent BioSolutions; upfront licensing fee of
$1 million, potential milestone payments of up to $20.4 million

John Dawson, Chief Executive Officer at Oxford BioMedica, said: "We have made
good progress across our lead development programmes during the first half of
2010. The long-term safety profile and sustained benefit of ProSavin is
extremely promising and the new administration method has the potential to add
significant value to this programme. With our partner sanofi-aventis we remain
focused on advancing all four ocular programmes into clinical development during
the next twelve months and also look forward to the Phase II development of
TroVax . These achievements have strengthened our pipeline and established a
strong platform from which to build a sustainable, profitable organisation.
Encouraging discussions continue regarding prospective partnerships and we
remain committed to achieving our strategic and commercial goals."

-Ends-

Oxford, UK - 22 September 2010: Oxford BioMedica ("the Company") (LSE: OXB), a
leading gene therapy company, today announces that TroVax , its therapeutic
cancer vaccine, has been selected by Windhover and Campbell Alliance as one of
the "Top 10 Most interesting Oncology Projects to Watch". TroVax was nominated
by a committee that included Windhover Information and the publishers of In Vivo
and Start Up industry publications.

That "vote" raised the sp but there wasn't any "prize-money" as I recall - and the sp is slipping back sooner than I'd like.

breakout above 10p could now be the time with plenty of expected newsflow over coming mths

Oxford Biomedica PLC Interim Management Statement



TIDMOXB

RNS Number : 1988V
Oxford Biomedica PLC
29 October 2010


OXFORD BIOMEDICA PLC
INTERIM MANAGEMENT STATEMENT

Oxford, UK - 29 October 2010: Oxford BioMedica plc ("Oxford BioMedica" or "the
Company") (LSE: OXB), a leading gene therapy company, today publishes its
interim management statement for the period from 1 July to 28 October 2010.

PIPELINE UPDATE
ProSavin (gene-based therapy for Parkinson's disease): development update
� Ninth patient now treated in third cohort (2x dose using enhanced
administration technique); Data Monitoring Committee (DMC) to assess results in
December
� Subject to DMC approval, treatment of final dose cohort expected to start
in Q1 2011
� Approval received from UK Medicines and Healthcare products Regulatory
Agency (MHRA) for a second clinical site in Cambridge, UK; expected to open in
December

ProSavin : regulatory update
Oxford BioMedica works closely with the European Medicines Agency (EMA) and US
Food and Drug Administration(FDA) on the development of its pipeline products
and in June 2010 the Company received formal scientific advice from the EMA on
the development path for ProSavin which validates the current strategy to
ensure rapid progress through to registration.

As previously reported, Oxford BioMedica submitted orphan drug applications to
the EMA and FDA for the use of ProSavin in a subset of patients with advanced
Parkinson's disease. In September the EMA decided that ProSavin may be of
significant benefit to a much broader patient population and therefore orphan
drug designation is not appropriate. The FDA also indicated that the patient
numbers in the proposed target population exceed the threshold for orphan drug
designation. These opinions support the worldwide potential for ProSavin in
the treatment of Parkinson's disease.

Ocular programmes (gene-based therapies targeting vision loss): development
update
� RetinoStat investigational new drug (IND) application submitted to the
FDA in September
� Subject to IND approval, RetinoStatPhase I/II trial expected to commence
in December
� StarGenTM clinical trial application (CTA) dossier on track for
submission by year-end

TroVax (therapeutic cancer vaccine): development update
� First patient treated in Phase II hormone refractory prostate cancer
trial
� Phase I/II sponsored study in mesothelioma expected to start in Q1 2011
� Discussions continue for sponsored trials in other cancer indications

FINANCIAL REVIEW
The Company's net cash1 balance at 30 June 2010, as reported in the interim
report, was GBP16.3 million. At 30 September 2010 the Company had a net cash1
balance of GBP13.7 million. Both figures are unaudited.

OUTLOOK
There are a number of important pipeline development milestones expected over
the next 12-18 months. The Company looks forward to the progression of
ProSavinto the next dose level in Q1 2011 and the subsequent data, the further
clinical development of TroVax with its clinical oncology collaborators and the
initiation of Phase I/II clinical development programmes for all four of its
ocular products, partnered with sanofi-aventis.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "We believe that
there is considerable value to be extracted from our three major programmes and
all efforts are focused on securing commercial success. With six pipeline
products on track to be in active clinical development by the end of 2011, we
remain committed to managing our financial resources and seeking strong
collaborations in order to maximise the return across our development pipeline."

-Ends-

mms seem to be forcing sp down on very thin trading> New yr tips normally feature OXB as the breakout biotech. Could happen next yr with Prosavin trials, Trovax progress and potential licencing agreements, not to mention the possibility of breakthrough in their occular technologies. Easily tipped when sp is on the floor, the whole co worth a miniscule 45m with cash in the bank of 14m. Surely a Takeover target at this level for the big boys who need new bio programmes

Sold of my holding to finance avn... looks like bad news tomorrow?...will get back in if price drops to 5-6p...Frustrating stock...frustrating sector..

Proposed Fundraising



TIDMOXB

RNS Number : 8096X
Oxford Biomedica PLC
13 December 20

OXFORD BIOMEDICA plc Proposed Firm Placing and Placing and Open Offer of up to GBP20 million Oxford BioMedica a biopharmaceutical company developing gene-based medicines and therapeutic vaccines, is pleased to announce that it intends to raise up to GBP20 million by way of a firm placing of up to 278,916,543 new ordinary shares of 1 pence each (the "New Ordinary Shares") (the "Firm Placing") and a placing and open offer of up to 121,083,457 New Ordinary Shares (the "Placing and Open Offer)" at a price of 5 pence per New Ordinary Share

Insiders knew of this on Thu/Fri of last weekmultiples of the daily average were soldwe all guessed what was comingand Bingoa rushed through RNS at 7-45...
Not too difficult to work outbut I feel a little too difficult for the FSA.
No change there then!!!.. market.abuse@fsa.gov.uk